Bruker Corp Acquires Canopy Biosciences
Ticker: BRKRP · Form: 8-K · Filed: May 31, 2024 · CIK: 1109354
| Field | Detail |
|---|---|
| Company | Bruker Corp (BRKRP) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $67.29 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, definitive-agreement, life-sciences
Related Tickers: BRUK
TL;DR
Bruker buys Canopy Biosciences to boost its life science tech.
AI Summary
On May 29, 2024, Bruker Corporation entered into a Material Definitive Agreement related to its acquisition of Canopy Biosciences, LLC. The agreement outlines the terms and conditions for this acquisition, which is expected to expand Bruker's capabilities in the life science research market.
Why It Matters
This acquisition signifies Bruker's strategic move to enhance its life science offerings, potentially leading to new product development and market expansion.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies.
Key Players & Entities
- Bruker Corporation (company) — Registrant
- Canopy Biosciences, LLC (company) — Acquired entity
- May 29, 2024 (date) — Date of Material Definitive Agreement
FAQ
What is the primary purpose of the Material Definitive Agreement filed by Bruker Corporation?
The primary purpose is to outline the terms and conditions for the acquisition of Canopy Biosciences, LLC.
When was the Material Definitive Agreement entered into?
The agreement was entered into on May 29, 2024.
Which company is Bruker Corporation acquiring?
Bruker Corporation is acquiring Canopy Biosciences, LLC.
What is Bruker Corporation's principal executive office address?
Bruker Corporation's principal executive office is located at 40 Manning Road, Billerica, MA 01821.
What is the Commission File Number for Bruker Corporation's 8-K filing?
The Commission File Number is 001-30833.
Filing Stats: 821 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-05-31 16:10:22
Key Financial Figures
- $0.01 — nge on Which Registered Common Stock, $0.01 par value per share BRKR The Nasdaq
- $67.29 — ement at a price to the Underwriters of $67.29 per share (the "offering price"). Pursu
Filing Documents
- tm2416150d1_8k.htm (8-K) — 31KB
- tm2416150d1_ex1-1.htm (EX-1.1) — 241KB
- tm2416150d1_ex5-1.htm (EX-5.1) — 6KB
- tm2416150d1_ex99-1.htm (EX-99.1) — 9KB
- tm2416150d1_ex99-2.htm (EX-99.2) — 8KB
- tm2416150d1_ex5-1img003.jpg (GRAPHIC) — 6KB
- tm2416150d1_ex5-1img004.jpg (GRAPHIC) — 17KB
- 0001104659-24-067154.txt ( ) — 563KB
- brkr-20240529.xsd (EX-101.SCH) — 3KB
- brkr-20240529_lab.xml (EX-101.LAB) — 33KB
- brkr-20240529_pre.xml (EX-101.PRE) — 22KB
- tm2416150d1_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On May 29, 2024, the Company issued press releases announcing that it had launched and priced the Offering. Copies of the press releases are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit Number Description 1.1
Underwriting
Underwriting Agreement, dated May 29, 2024, by and among Bruker Corporation and BofA Securities, Inc. and J.P. Morgan Securities LLC 5.1 Opinion of Morgan, Lewis & Bockius LLP 23.1 Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1) 99.1 Press Release dated May 29, 2024 99.2 Press Release dated May 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRUKER CORPORATION (Registrant) Date: May 31, 2024 By: /s/ GERALD N. HERMAN Name: Gerald N. Herman Title: Executive Vice President and Chief Financial Officer